ライフサイエンスコーパス: phase III clinical trial

1 ntation, however, has not been verified in a phase III clinical trial.

2 n vivo and is currently being evaluated in a Phase III clinical trial.

3 red for adjuvant therapy in the setting of a phase III clinical trial.

4 provides strong rationale for a confirmatory phase III clinical trial.

5 te therapeutic benefit against melanoma in a phase III clinical trial.

6 ested as a neuroprotective agent for PD in a phase III clinical trial.

7 prospective, multicenter, placebo-controlled Phase III clinical trial.

8 , and to determine if it merits testing in a Phase III clinical trial.

9 difficult course with 3 compounds failing in phase III clinical trials.

10 , a prodrug of which is currently undergoing phase III clinical trials.

11 tease inhibitor that is currently undergoing phase III clinical trials.

12 ctivity that currently is being evaluated in phase III clinical trials.

13 than single-agent cisplatin when compared in phase III clinical trials.

14 1,681 Candida isolates (16 species) from the phase III clinical trials.

15 clinical experience and describe the ongoing phase III clinical trials.

16 Two of them, Macugen and E2F decoy, are in phase III clinical trials.

17 e agents are being tested in new large-scale phase III clinical trials.

18 nt treatments for micrometastatic disease in phase III clinical trials.

19 e to take a small number of these through to phase III clinical trials.

20 significant redistribution and currently in phase III clinical trials.

21 i-cancer drug cisplatin that is currently in phase III clinical trials.

22 romising chemotherapeutic agent currently in Phase III clinical trials.

23 6 months after renal transplantation in two phase III clinical trials.

24 se II, phase III) or have recently completed phase III clinical trials.

25 ant recipients who participated in these two phase III clinical trials.

26 onsiderations for the design of phase II and phase III clinical trials.

27 cipal investigators in the phase I/II and/or phase III clinical trials.

28 ng engorgement and is a vaccine candidate in phase III clinical trials.

29 rants further investigation of this agent in phase III clinical trials.

30 fficacy against EBOV infections in humans in phase III clinical trials.

31 argeting HCMV terminase that is currently in phase III clinical trials.

32 pecially with phage therapy advancing toward phase III clinical trials.

33 by positive results from recently completed phase III clinical trials.

34 remain, these trials hold promise for future phase III clinical trials.

35 a poxvirus-based cancer vaccine currently in phase III clinical trials.

36 ed many Met inhibitors, some of which are in phase III clinical trials.

37 linical models, most therapies still fail in phase III clinical trials.

38 lective inhibitors are already being used in phase III clinical trials.

39 unction on the LDL receptor are evaluated in phase III clinical trials.

40 s cobimetinib), a MEK inhibitor currently in phase III clinical trials.

41 onstrate significant therapeutic efficacy in phase III clinical trials.

42 is considered a major therapeutic target in phase III clinical trials.

43 re currently being evaluated in phase II and phase III clinical trials.

44 l ester (bardoxolone methyl) is presently in phase III clinical trials.

45 In Europe, ferumoxtran-10 is entering phase III clinical trials.

46 ide in Diabetic Macular Edema (FAME) A and B Phase III clinical trials.

47 g telomerase directly and immunologically to phase III clinical trials.

48 0) and from Gynecologic Oncology Group (GOG) phase III clinical trials 218 (n = 788) and 262 (n = 557

49 nternational double-blind placebo-controlled phase III clinical trial, 428 patients who had active rh

50 As part of this phase III clinical trial, a central pathologist evaluate

51 om 80 patients participated in a prospective Phase III clinical trial addressing the dose and fractio

52 ectal Cancer Study Group 8) study is a large phase III clinical trial addressing the sequence strateg

53 cience supporting this role, and analyze the phase III clinical trials addressing the association bet

54 , because nifurtimox is currently undergoing phase III clinical trials against African trypanosomiasi

55 vaccine for melanoma, which are currently in phase III clinical trials: allogeneic and autologous cel

56 across nearly every subgroup examined in the phase III clinical trial and has an acceptable safety pr

57 tematic literature review and identified two phase III clinical trials and a randomized phase II dose

58 ajor public health concern with few positive phase III clinical trials and a shortage of stroke care

59 than that of (-)-epigallocatechin gallate in Phase III clinical trials and about one order of magnitu

60 earch of the MEDLINE database, we identified phase III clinical trials and pharmacologic studies comp

61 R115777 has been evaluated in phase III clinical trials and shows indications for the

62 erivative linezolid 2, which is currently in phase III clinical trials, and the piperazine derivative

63 A number of randomized phase III clinical trials are currently underway to furt

64 Definitive, randomized, placebo-controlled phase III clinical trials are needed to determine whethe

65 Phase III clinical trials are now underway examining the

66 Phase III clinical trials are now underway, given the pr

67 anespimycin), which is currently in phase II/phase III clinical trials, are promising new anticancer

68 onase is an amphibian protein that is now in Phase III clinical trials as a cancer chemotherapeutic.

69 the last 12-18 months, no drug has completed phase III clinical trials as a clearly proven method to

70 ribonuclease A (RNase A) superfamily, is in phase III clinical trials as a treatment for malignant m

71 out an EGFRK-specific inhibitor currently in Phase III clinical trials as an anti-cancer agent, erlot

72 myocardial salvage index, indicating that a phase III clinical trial assessing intracoronary nitrite

73 ated in association with chemotherapy in two phase III clinical trials, both in the treatment and in

74 f patients with metastatic CRC (mCRC) of two phase III clinical trials, CAIRO and CAIRO2.

75 All patients were participants of a phase III clinical trial (CAO/ARO/AIO-94, German Rectal

76 NCCTG N9831 is a randomized, phase III clinical trial comparing three drug regimens:

77 clinical testing and has progressed through phase III clinical trials, continued efforts are underwa

78 Data from phase III clinical trials demonstrate that the standard

79 Isolates from 2 phase III clinical trials demonstrated that fidaxomicin

80 ntegration of molecular targeted agents into phase III clinical trial design has lagged in the curati

81 says, the Mammaprint and Oncotype Dx, are in phase III clinical trials designed to evaluate their con

82 into the Eastern Cooperative Oncology Group phase III clinical trial E9486 and associated laboratory

83 he Eastern Cooperative Oncology Group (ECOG) phase III clinical trial E9486.

84 ipants, 22.2% met typical entry criteria for phase III clinical trials (efficacy sample) and 77.8% di

85 This phase III clinical trial evaluated the impact on disease

86 In a prospective, randomized phase III clinical trial evaluating the activity of tras

87 temic therapies and the results of the first phase III clinical trial evaluating the addition of inip

88 Phase III clinical trials evaluating bevacizumab (an ant

89 in patient outcomes despite many randomized phase III clinical trials evaluating multiple agents, bo

90 including the first results from randomized phase III clinical trials evaluating the efficacy of bev

91 configuration deoxycytidine analog, is under phase III clinical trial for cancer treatment.

92 data support investigation of efficacy in a phase III clinical trial for newly diagnosed HRNB.

93 mpound 17 successfully completed a long-term phase III clinical trial for pulmonary arterial hyperten

94 that a related iminosugar DGJ (currently in phase III clinical trials for another metabolic disorder

95 ibitors are emerging as anti-cancer drugs in phase III clinical trials for BRCA-deficient tumors.

96 hanistically unique microtubule inhibitor in phase III clinical trials for cancer, exhibits superior

97 Eribulin is currently undergoing phase III clinical trials for cancer; ER-076349 is a clo

98 Phase III clinical trials for depression enroll particip

99 In pivotal phase III clinical trials for detecting recurrent or met

100 most robust evidence from large phase II and phase III clinical trials for ranibizumab demonstrated v

101 the blood-brain barrier and is currently in phase III clinical trials for several types of cancer.

102 oderate but positive results in two separate phase III clinical trials for SLE, and was recently reco

103 al agonist of hGPR40 receptor, which reached phase III clinical trials for the potential treatment of

104 Human gene-2 (H2) relaxin is currently in Phase III clinical trials for the treatment of acute hea

105 marine natural product halichondrin B, is in phase III clinical trials for the treatment of cancer.

106 ive antiangiogenic drug that is currently in phase III clinical trials for the treatment of castratio

107 hibitor of the NS3/4A enzyme is currently in phase III clinical trials for the treatment of hepatitis

108 of human anti-CTLA-4 antibody, currently in phase III clinical trials for the treatment of melanoma.

109 antagonist that is currently being tested in phase III clinical trials for the treatment of primary i

110 SC-58635, celecoxib), which is currently in phase III clinical trials for the treatment of rheumatoi

111 ncluding Onconase, an amphibian homologue in phase III clinical trials for the treatment of unresecta

112 iplatelet agent that is currently undergoing Phase-III clinical trials for acute coronary syndrome (u

113 Four phase III clinical trials form the primary evidence base

114 Prospective phase III clinical trials have demonstrated advanced dia

115 Recent results from phase III clinical trials have demonstrated that in pati

116 However, more rigorous phase II and phase III clinical trials have failed to unequivocally d

117 against HIV infection observed in the RV144 phase III clinical trial highlighted the need for furthe

118 In a recently completed phase III clinical trial, however, IL13-PE38QQR was foun

119 trapib, the first CETP inhibitor tested in a phase III clinical trial (ILLUMINATE), failed in 2006 be

120 adipine is currently undergoing testing in a phase III clinical trial in early PD.

121 Results from phase III clinical trials in adults and phase II clinica

122 Phase III clinical trials in cancer should have much bro

123 Several phase III clinical trials in locally advanced squamous h

124 inhibitor in clinical testing, with ongoing phase III clinical trials in patients with chronic lymph

125 on the minimum evidence required to justify phase III clinical trials in the critically ill populati

126 Combined results are reported from 2 phase III clinical trials in which a total of 497 subjec

127 Phase III clinical trials initiated in 1997-98 using mar

128 atment of Cancer (EORTC) 26951, a randomized phase III clinical trial investigating adjuvant procarba

129 e sepsis models and is under evaluation in a phase III clinical trial involving patients with severe

130 iple time-consuming, expensive, and negative phase III clinical trials involving many thousands of pa

131 complexity, the overall development time for phase III clinical trials is lengthy, process laden, and

132 d direct thrombin inhibitor drugs completing phase III clinical trials, it is likely that additional

133 tically designed, multicenter, double-blind, phase III clinical trials (MM-009 and MM-010) were condu

134 s of tumors from 135 patients entered into a Phase III clinical trial of 5FU-based adjuvant therapy.

135 A randomized phase III clinical trial of adjuvant active specific imm

136 hase II clinical trial of liver cancer and a phase III clinical trial of advanced non-small-cell lung

137 A recent phase III clinical trial of an sPLA2 inhibitor (varespla

138 ability of Avastin to prolong survival in a Phase III clinical trial of human colorectal cancer has

139 hat are likely to demonstrate effectiveness (phase III clinical trials of adenosine in acute myocardi

140 tly, this year the results of two randomized phase III clinical trials of chemotherapy in hormone ref

141 Data from Phase III clinical trials of new immunosuppressants, how

142 Data from two phase III clinical trials of omalizumab in patients with

143 complete rotavirus genomes collected during phase III clinical trials of RotaTeqTM in Sub-Saharan Af

144 SVR at various post-treatment time points in phase III clinical trials of sofosbuvir (SOF)-containing

145 the new oral anticoagulants (OACs) in large phase III clinical trials of stroke prevention in atrial

146 We identified all phase III clinical trials of targeted therapies against

147 Among the phase III clinical trials only the RV144 vaccine trial e

148 ation acute coronary syndrome enrolled in 11 phase III clinical trials over 17 years (1994-2010).

149 imal exclusion criteria--to evaluate whether phase III clinical trials recruit representative depress

150 2 independent randomized placebo-controlled phase III clinical trials (REFLEX [Randomized Evaluation

151 : As evidenced by recently reported positive phase III clinical trials, secondary hormonal agents suc

152 fore using this regimen in general practice, phase III clinical trials should be conducted.

153 Phase III clinical trials should be implemented only if

154 A phase III clinical trial showed that MEDI-493 significan

155 Phase III clinical trials showing a survival advantage i

156 Recent successful phase III clinical trials showing benefit to the patient

157 el-targeted TNFalpha derivative currently in phase III clinical trials, substituted for Y-redirected

158 Currently in phase III clinical trials, sugammadex has been shown to

159 2i epitope." IMPORTANCE: Data from the RV144 phase III clinical trial suggested that the presence of

160 Two pivotal phase III clinical trials, TAX 327 and SWOG 9916 have de

161 Nonetheless, phase III clinical trials that have attempted to antagon

162 currently in phase H and at least one is in phase III clinical trial, the mechanism of FTI antitumor

163 As the JAK2 inhibitors move into phase III clinical trials, their efficacy and role in th

164 We conducted a randomized phase III clinical trial to compare the efficacy and tox

165 We conducted a phase III clinical trial to determine whether the additi

166 nt development stages, from the lab bench to phase III clinical trials to clinical practice.

167 pression profile, Rv1980c is currently under phase III clinical trials to evaluate its potential to r

168 Compared with the phase III clinical trial vaccine, GH-keyhole limpet hemo

169 A prospective randomized phase III clinical trial was conducted to assess whether

170 antisepsis agent to successfully complete a phase III clinical trial was human recumbent activated p

171 ization protocol mimicking that of the RV144 phase III clinical trial was used.

172 es from breast cancer who were enrolled in a phase III clinical trial were evaluated before treatment

173 onto the most recent Children's Cancer Group phase III clinical trials were assayed for LOH with 13 m

174 closely related to a drug that is undergoing phase III clinical trials, were chosen to determine the

175 approaches are being used or are in phase II/phase III clinical trials, which may be available in cli

176 In the near future, phase III clinical trials will elucidate the role of the

177 Double-blind, multicenter, randomized Phase III clinical trials with benzoporphyrin derivative

178 h the active enrollment of CHD patients into phase III clinical trials with both classes of inhibitor

179 Phase III clinical trials with hypothermia have been suc

180 e is a polymerized human hemoglobin in early phase III clinical trials with trauma patients, having i

181 rative oncology groups are major sponsors of phase III clinical trials, yet the time and steps requir